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Abstract
Therapeutic drugmonitoring (TDM) of antibiotics has been practiced for more than half a century, but it is still not widely applied
for infected patients. It has a traditional focus on limiting toxicity of specific classes of antibiotics such as aminoglycosides and
vancomycin. With more patients in critical care with higher levels of sickness severity and immunosuppression as well as an
increasingly obese and ageing population, an increasing risk of suboptimal antibiotic exposure continues to escalate. As such, the
value of TDM continues to expand, especially for beta-lactamswhich constitute the most frequently used antibiotic class. To date,
the minimum inhibitory concentration (MIC) of infectious microbes rather than classification in terms of susceptible and resistant
can be reported. In parallel, increasingly sophisticated TDM technology is becoming available ensuring that TDM is feasible and
can deliver personalized antibiotic dosing schemes. There is an obvious need for extensive studies that will quantify the
improvements in clinical outcome of individual TDM-guided dosing. We suggest that a broad diagnostic and medical investi-
gation of the TDM arena, including market analyses and analytical technology assessment, is a current priority.
Introduction
The need for precise measurement of antimicrobial agents in the
blood of patients to follow treatment success or failure was
recognized early on [1]. Traditionally, this therapeutic drug mon-
itoring (TDM) of antibiotics has primarily involved quantitative
drug measurements in patient’s plasma to minimize toxicity risks
with agents of narrow therapeutic indices [2, 3]. Still for antibi-
otics, TDM was used sparingly such as for vancomycin, chlor-
amphenicol and the aminoglycosides [4]. The general target pop-
ulation were and still are patients in acute care situations or those
hospitalized for longer term care and treatment (e.g. [5]). A more
advanced TDM practice, however, is emerging with an aim to
ensure efficacy as well as minimizing toxicity of a broader spec-
trum of antibiotics with relatively wider therapeutic indices. It
takes advantage of a better definition of the optimum antibiotic
exposure for therapeutic success. Antibiotic pharmacokinetics
(PK) is commonly defined as ‘what does the body do to the drug’
during its complete cycle in vivo, whereas pharmacodynamics
(PD) relates to ‘what the drug does to themicroorganism in vivo’,
the interplay between the two, ‘PK/PD’, defining the optimum
antimicrobial activity achievable for the unbound drug concen-
trations at the site of infection. Consensus studies and guidelines
have helped to propose values for these PK/PD targets, specific
for an antibiotic in combination with a clinical condition [6–8].
By comparing drug plasma concentration data (a surrogate for
the site of infection) to these predefined PK/PD targets, a person-
alized antibiotic dosing practice can help ensure an optimized
antibiotic exposure. Personalized treatment will apply to an
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increasing population of high-risk patients and will have addi-
tional impact on the fight against antimicrobial resistance (AMR)
by significantly improving the optimal usage of our pharmaco-
poeia. Finally, a reduced developmental pipeline for new antibi-
otics is necessitating that we spare last resort drugs with TDM
considered instrumental for protecting this precious antimicrobial
armamentarium (e.g. [9]).
Here, we succinctly review the current status of TDM in the
field of antibiotic therapy. Despite the fact that significant
progress has been made in various disciplines in the field of
TDM, there st i l l seems to be a restr icted global
implementation.
Sub-optimal antibiotic exposure in high-risk
patient groups
The majority of drug dosing regimens has been defined in
healthy adults at the time of drug development where there
was no resistance to those drugs. The lack of variability in PK
and patient characteristics in those initial studies is not a rep-
resentative of the breadth of patients in whom these drugs will
be used and the ultimate exposure levels of such patients. It is
highly unlikely that this “one dose fits all” strategy will max-
imize antibiotic effectiveness in all patients. Unpredictable
drug concentrations in plasma and other body compartments
due to altered volume of distribution and clearance may result
from factors as diverse as acute pathophysiology during crit-
ical care admission (such as sepsis and immuno-suppression),
obesity [10], early ages [11], advanced age, surgical prophy-
laxis for longer invasive procedures [12], cystic fibrosis [13],
the use of techniques for organ replacement in case of organ
failure (extracorporeal membrane oxygenation (ECMO)) and
renal replacement therapy (RRT) [14, 15]. To add to these
significant alterations of PK in critically ill patients, the PD
target might be different depending on the indications. (e.g.
skin and soft tissue versus pulmonary infections).
As a consequence, a growing body of evidence links sub-
therapeutic antibiotic concentrations with treatment failure.
For example, the “Defining Antibiotic Levels in Intensive
Care Unit (ICU) patients” (DALI) study showed that up to
70% of critically ill patients in the ICU did not meet the PK/
PD targets defined for beta-lactams, and that those patients
with the lowest exposures were more likely to have a negative
treatment outcome (treatment course with change or addition
of antibiotic therapy, in particular within 48 h of cessation)
[16]. Similar data are available for other antibiotics including
meropenem [17], other beta-lactams [18–20], vancomycin
[21–23], and ciprofloxacin [22, 24]. Both the studies by
Moise-Broder et al. [21] and Martirosov et al. [23] show sig-
nificant differences between optimal and suboptimal treatment
of staphylococcal infection where the area under the curve
(AUC) for 24 h of treatment below or under the minimum
inhibitory concentration (MIC) value is statistically signifi-
cant. The combined analysis of 179 patients clearly show that
optimal vancomycin dosing is an important denominator of
clinical and microbiological success. The use and therapeutic
success of intravenous ciprofloxacin in 74 patients was shown
to be dosing dependent [24]. Low dosing at 200 mg for every
12 h versus higher dosing at 400 mg every 8 h resulted in
different overall drug concentrations in the blood and were
clearly associated with slower eradication of the infecting or-
ganism in the low concentration treatment group. Of note,
additional patient’ characteristics have a distinct effect on an-
tibiotic concentration in the circulation. Carrie et al. [20] show
that augmented renal clearance of beta-lactams resulted in
suboptimal antibiotic concentrations in serum for 12% of the
patients and with that a significant effect on clinical and bac-
terial cure. Sub-optimal dosing and its clinical consequences
is a domain of important research that should be thoroughly
included in any development protocol for new antimicrobials.
Optimized dosing for reducing selection
of resistance
The decreasing antibiotic susceptibility of pathogens may re-
quire higher antimicrobial dosing to achieve a therapeutic ex-
posure that maximizes treatment success [25]. Still, dosing
regimens for a new drug are initially defined by targeting
‘wild type’ susceptible pathogens, from which are derived
the so-called ecological cut-off values (ECOFF) (MIC distri-
bution separating bacterial populations into wild type and
those with acquired or mutational resistance, see for instance
[26] or the European Committee for Antimicrobial
Susceptibility Testing (EUCAST) definition of wild type bac-
terial isolates). When a non-wild type pathogen emerges,
higher doses may have to be used even if its higher MIC still
falls within the susceptible or in the intermediate categories.
As physicians tend to exclude antibiotics associated with in-
termediate MICs in favour of alternative antibiotics for which
the bacterial strain is still fully susceptible, potent broad spec-
trum antimicrobials are often used [27]. Within this context,
the EUCAST and Clinical and Laboratory Standards Institute
(CLSI) committees recently promoted new increased dosing
regimen categories in order to help spare last resort antibiotics
(see EUCAST (www.eucast.org) and CLSI (www.clsi.org)
websites for more detail). Thus, the dynamics of what the
antibiotic does to the infectious bacteria in vivo has to be
revised according to the MIC of the strain. EUCAST
representatives suggest to integrate inherent experimental
variability of MIC testing into the calculation of PK/PD tar-
gets by applying the following rules [28]. First, if theMIC is in
the wild type category (susceptible organism) and lower than
the ECOFF, then the ECOFF value should be used as the MIC
value in the calculation of the PK/PD index. Second, if the
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MIC is above the ECOFF, then a ×4 MIC value should be
used. Thus, stricter adherence to antimicrobial susceptibility
testing (AST) guidelines will make the data generated by
TDM even more clinically useful. It has to be acknowledged
though thatMICs represent a marker based on a single point in
time and concentration. In addition, measuring an MIC is no
sinecure and significant variability within and between
methods exists [29]. Not everything will be solved by simple
adherence to guidelines, and there is a need for further studies
into optimized dosing as a consequence of regional prevalence
of antibiotic resistance [30].
Patient outcomes and PK/PD target
attainment
An increased body of knowledge provides evidence for ben-
efits associated with PK/PD target attainment, including vari-
ations in the dosing schemes, in terms of lower mortality,
clinical cure, reduced length of stay and lower toxicity, as
shown for many antibiotics. For example, continuous infusion
as opposed to short-term infusion can help to reach more
effective PK/PD targets and improve efficacy in case of sepsis
where mortality can be reduced up to 30% [31, 32].
Vancomycin [33, 34], beta-lactams [35, 36], aminoglycosides
[37, 38], quinolones [24, 39], linezolid [40], daptomycin [41]
and even antifungals [42] have been studied in adequate detail
although it has to be admitted that not all studies uniformly
showed clinical benefit.
Few studies have evaluated the impact of active TDM per se
on the clinical course of critical care patients in prospective
randomized trials [43], except maybe in the on-going
“DIABOLO” and “OPTIMAL TDM” clinical trials [44].
These studies show that TDM improves antibiotic exposure
by guiding PK/PD target attainment. This will potentially help
reduce the early development of antibiotic resistance as evi-
denced in preclinical infection models [45, 46] and adds weight
to the call for active TDM of all patients, for which high PK
variability is expected. This is corroborated by Jacobs et al. [47]
who showed that a simple creatinine clearance measure cannot
be used to predict and adjust the beta-lactam plasma concentra-
tion in septic patients with augmented renal clearance [48].
Independently, TDM was proven to be cost-effective for
streamlining aminoglycoside use [49]. This can only be true
for newer, hence more costly antibiotics. Thus, it can be con-
cluded that, if managed correctly, TDM is profitable for patient
management and the health economy simultaneously.
Monitoring of antibiotic concentrations today
From a historical perspective, TDM has been adopted mostly
to prevent adverse toxicity effects, mainly for glycopeptides
and aminoglycosides. Apart from the assessment of trough
concentrations, also the determination of peak concentrations
was considered to be diagnostically and, hence, therapeutical-
ly important. TDM of trough concentrations still is strongly
recommended for all patients using the aforementioned anti-
biotics [17, 50].
However, TDM is now on a slow rise in broader use to
ensure optimum antibiotic exposure, in particular to avoid
under-dosing, with evidence existing for many antibiotic clas-
ses including beta-lactams, linezolid and daptomycin (see
statements above). With regard to beta-lactams, the most com-
monly monitored drugs are piperacillin-tazobactam and
meropenem, followed by ceftazidime [51]. Data required in-
clude the concentration of the antibiotic in the patient’s plas-
ma, which is quantified either by a specialized pharmacology
or biochemistry laboratory, as well as the MIC of the infec-
tious microorganism, a result originating from the microbiol-
ogy lab. These data are then consolidated with other clinical
parameters (patient weight, comorbidities, renal function, etc.)
TDM may be managed by routine hospital laboratories or
more specialized independent laboratories either or not
“Clinical Laboratory Improvement Amendments” (CLIA)
compatible or waived.
Technologies used for TDM
The most commonly used method for current TDM involves
immunological assaying, mostly using closed systems and
automated chains. These are used in commercial kits for ‘tox-
ic’ antibiotics like vancomycin and aminoglycosides and are
mostly appreciated for their rapidity. However, standardiza-
tion and calibration of this type of testing is not always easy.
Immunoassays are often adapted to open chemistry main-
stream chains to lower the overall cost (e.g. CEDIA by
ThermoFisher Scientific and Roche, enzyme multiplied im-
munoassay technique (EMIT) by Olympus Chemistry
Systems and the tests provided by Randox Laboratories
(Crumlin, UK)).
The second most used technology is that of liquid chroma-
tography (LC) which is often combined with mass spectrom-
etry (LC-MS). LC-MS uses mostly locally developed assays
and protocols, which provides a level of experimental flexi-
bility that can be easily adapted to commonly applied antibi-
otics. LC-MS is a highly adaptable technology, and when
internal standard molecular markers are available and the
equipment and associated personnel are within financial
reach, this is a good diagnostic choice. On the other hand,
duration of MS technologies (24–96 h) may pose a significant
obstacle to clinical use. Application of LC-MS requires the
employment of an expert scientist which makes a 24-h service
difficult. The technology is not available in all laboratories but
mainly in metropolitan-based laboratories which often leads
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to delayed or prolonged time to result. Actually, various forms
of point of care testing are currently being developed and
prototypes are being experimented with. The use of biosensor
technologies has been proposed, superficially explored and
the first results are promising [52–54]. In the latter study,
elegant microneedle-based biosensors were used for beta-
lactam detection. Recent publications revealed the successful
use of microfluidic devices for monitoring aminoglycoside or
beta-lactam concentrations in whole blood with a wide dy-
namic range [55, 56]. The development of such miniaturized
and potentially automatable methods can better position TDM
in routine microbiology laboratories, particularly if they are
shown to be cost-effective. The assaying of body fluids that
can be obtained non-invasivelymaymake TDMmore feasible
[57]. The major current need are large-scale clinical validation
studies for these new technologies. As stated before: none of
the currently available methods adequately distinguished be-
tween the bound and unbound fractions of antibiotics.
Clinical timing of TDM
It is suggested that for clinical application of TDM, one or two
TDM measurements should be made during the very first
dosing interval of the antibiotic treatment, then updated as
much as needed after 48 h or before, depending on the antibi-
otic. The data can then be compared with PK models for
specific populations, now available in any one of various soft-
ware solutions that estimate the dose to use [58]. In practice,
this is difficult because antibiotics might have short half-lives
(4 h and 6 h on average for β-lactams and vancomycin, re-
spectively). Defining the best sampling time may be problem-
atic since the prescription strategy often relies on repeated
antibiotic administration. This underlines the need for well-
documented, written protocols for managing TDM. Another
challenge is that the total turnaround time (TAT) of TDMmay
be too long if the required expertise is not available as a per-
manent service. This includes the need for sometimes compli-
cated and lasting pre- and post-analytical procedures; total
TDM TAT ranges between 2 h to sometimes even 24 h, aver-
aging 18–24 h (personal communications with various TDM
users). With the actual TDM test being relatively quick in
itself (ca. 30 min), the overall TAT is limited by logistics and
pre- and post-analytical processes. This underscores the need
for a simple-to-operate and easy-to-interpret test that must be
continuously available to help increase the operability of
TDM.
Of additional interest is the previously already mentioned
use of continuous infusion of antibiotics in the ICU [31, 59].
The first intelligent devices that can perform this in an intrin-
sically controlled fashion using concentration-based feedback
mechanisms are becoming tested in this field [60]. This also
translates into a considerable practical interest for TDM
because once the initial loading dose has attained its equilib-
rium, sampling and TDM can be done at any time, therefore
removing time constraint and kinetic uncertainty and enabling
a smoother use of TDM in the patient management workflow
[61]. In addition, the use of machine learning procedures to
develop algorithms that facilitate software-driven timing-inde-
pendent adaptation of individual treatment will become more
widespread in the near future.
Conclusion and recommendation
TDM should be clearly positioned as an integral part of the
antimicrobial stewardship program in hospitals given its piv-
otal role in antibiotic treatment optimization. This will enable
better delivery of the right antibiotic dose for the right patient
at the right moment and for the right duration. As such, it will
help combat the challenges provided by the growing AMR
problem. This personalized medicine perspective still requires
improvement to fully satisfy antibiotic prescribers. It is urgent
that the TAT of TDM be shortened significantly and that ac-
cessible point of care tests and rapid technology–based assays
enter the TDM market. Also, here are many practical ques-
tions around the implementation of TDM. How to coordinate
results coming from microbiology and clinical chemistry lab-
oratories? Who will integrate the data and issue a therapeutic
advice? Who will be adjusting antimicrobial therapy and
along which guidelines? When these issues have been re-
solved, TDM should become an integral part of the standard
testing portfolio of all self-respecting clinical microbiology
laboratories.
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